Exagen Inc. (NASDAQ:XGN) Receives $11.25 Consensus Price Target from Brokerages

Key Points

• Exagen Inc. has received a consensus rating of "Buy" from seven analysts, with an average 12-month target price of $11.25.
• Institutional investors own 75.25% of Exagen's stock, with several firms recently acquiring new positions in the company.
• Exagen reported a revenue of $17.20 million in its latest quarter, exceeding analysts' expectations of $16.25 million.

Shares of Exagen Inc. (NASDAQ:XGN - Get Free Report) have received an average rating of "Buy" from the seven research firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.25.

A number of brokerages recently commented on XGN. UBS Group reiterated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Craig Hallum started coverage on Exagen in a research report on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 target price on the stock. Canaccord Genuity Group increased their target price on Exagen from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. BTIG Research reissued a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Finally, KeyCorp raised Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price objective on the stock in a report on Wednesday, July 30th.

Exagen Stock Performance

XGN traded up $0.14 during trading hours on Friday, reaching $9.98. The company's stock had a trading volume of 156,568 shares, compared to its average volume of 367,471. The company's 50-day moving average is $7.84 and its 200-day moving average is $5.96. Exagen has a 52 week low of $2.38 and a 52 week high of $10.00. The firm has a market cap of $219.56 million, a PE ratio of -11.21 and a beta of 1.61. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Exagen has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Exagen will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Exagen

A number of hedge funds have recently bought and sold shares of the business. Bridgeway Capital Management LLC grew its position in shares of Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company's stock worth $194,000 after purchasing an additional 2,600 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after buying an additional 2,630 shares during the period. Huntleigh Advisors Inc. grew its position in Exagen by 5.7% during the second quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company's stock worth $613,000 after buying an additional 4,753 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Exagen during the first quarter worth approximately $25,000. Finally, Geode Capital Management LLC increased its stake in Exagen by 11.9% during the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock worth $402,000 after acquiring an additional 10,442 shares during the period. 75.25% of the stock is owned by institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).